BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30071532)

  • 1. SLC1A5 Silencing Inhibits Esophageal Cancer Growth via Cell Cycle Arrest and Apoptosis.
    Lin J; Yang T; Peng Z; Xiao H; Jiang N; Zhang L; Ca D; Wu P; Pan Q
    Cell Physiol Biochem; 2018; 48(1):397. PubMed ID: 30071532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutamine addiction activates polyglutamine-based nanocarriers delivering therapeutic siRNAs to orthotopic lung tumor mediated by glutamine transporter SLC1A5.
    Wang C; Wu J; Wang Z; Yang Z; Li Z; Deng H; Li L; Peng X; Feng M
    Biomaterials; 2018 Nov; 183():77-92. PubMed ID: 30149232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of circular RNA septin 9 inhibits the malignant progression of breast cancer by reducing the expression of solute carrier family 1 member 5 in a microRNA-149-5p-dependent manner.
    Wang J; Yang K; Cao J; Li L
    Bioengineered; 2021 Dec; 12(2):10624-10637. PubMed ID: 34738502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SLC1A5 mediates glutamine transport required for lung cancer cell growth and survival.
    Hassanein M; Hoeksema MD; Shiota M; Qian J; Harris BK; Chen H; Clark JE; Alborn WE; Eisenberg R; Massion PP
    Clin Cancer Res; 2013 Feb; 19(3):560-70. PubMed ID: 23213057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1,25-Dihydroxyvitamin D inhibits glutamine metabolism in Harvey-ras transformed MCF10A human breast epithelial cell.
    Zhou X; Zheng W; Nagana Gowda GA; Raftery D; Donkin SS; Bequette B; Teegarden D
    J Steroid Biochem Mol Biol; 2016 Oct; 163():147-56. PubMed ID: 27154413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting ASCT2-mediated glutamine uptake blocks prostate cancer growth and tumour development.
    Wang Q; Hardie RA; Hoy AJ; van Geldermalsen M; Gao D; Fazli L; Sadowski MC; Balaban S; Schreuder M; Nagarajah R; Wong JJ; Metierre C; Pinello N; Otte NJ; Lehman ML; Gleave M; Nelson CC; Bailey CG; Ritchie W; Rasko JE; Holst J
    J Pathol; 2015 Jul; 236(3):278-89. PubMed ID: 25693838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circ_0001273 downregulation inhibits the growth, migration and glutamine metabolism of esophageal cancer cells via targeting the miR-622/SLC1A5 signaling axis.
    Wu B; Chen Y; Chen Y; Xie X; Liang H; Peng F; Che W
    Thorac Cancer; 2022 Jun; 13(12):1795-1805. PubMed ID: 35567340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The glutamine transporter ASCT2 (SLC1A5) promotes tumor growth independently of the amino acid transporter LAT1 (SLC7A5).
    Cormerais Y; Massard PA; Vucetic M; Giuliano S; Tambutté E; Durivault J; Vial V; Endou H; Wempe MF; Parks SK; Pouyssegur J
    J Biol Chem; 2018 Feb; 293(8):2877-2887. PubMed ID: 29326164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TEAD1 (TEA Domain Transcription Factor 1) Promotes Smooth Muscle Cell Proliferation Through Upregulating SLC1A5 (Solute Carrier Family 1 Member 5)-Mediated Glutamine Uptake.
    Osman I; He X; Liu J; Dong K; Wen T; Zhang F; Yu L; Hu G; Xin H; Zhang W; Zhou J
    Circ Res; 2019 Apr; 124(9):1309-1322. PubMed ID: 30801233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting glutamine transport to suppress melanoma cell growth.
    Wang Q; Beaumont KA; Otte NJ; Font J; Bailey CG; van Geldermalsen M; Sharp DM; Tiffen JC; Ryan RM; Jormakka M; Haass NK; Rasko JE; Holst J
    Int J Cancer; 2014 Sep; 135(5):1060-71. PubMed ID: 24531984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting SLC1a5-mediated glutamine dependence in non-small cell lung cancer.
    Hassanein M; Qian J; Hoeksema MD; Wang J; Jacobovitz M; Ji X; Harris FT; Harris BK; Boyd KL; Chen H; Eisenberg R; Massion PP
    Int J Cancer; 2015 Oct; 137(7):1587-97. PubMed ID: 25821004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. miR-137 regulates ferroptosis by targeting glutamine transporter SLC1A5 in melanoma.
    Luo M; Wu L; Zhang K; Wang H; Zhang T; Gutierrez L; O'Connell D; Zhang P; Li Y; Gao T; Ren W; Yang Y
    Cell Death Differ; 2018 Aug; 25(8):1457-1472. PubMed ID: 29348676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upregulated SLC1A5 promotes cell growth and survival in colorectal cancer.
    Huang F; Zhao Y; Zhao J; Wu S; Jiang Y; Ma H; Zhang T
    Int J Clin Exp Pathol; 2014; 7(9):6006-14. PubMed ID: 25337245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SLC1A5 glutamine transporter is a target of MYC and mediates reduced mTORC1 signaling and increased fatty acid oxidation in long-lived Myc hypomorphic mice.
    Zhao X; Petrashen AP; Sanders JA; Peterson AL; Sedivy JM
    Aging Cell; 2019 Jun; 18(3):e12947. PubMed ID: 30909319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia.
    Willems L; Jacque N; Jacquel A; Neveux N; Maciel TT; Lambert M; Schmitt A; Poulain L; Green AS; Uzunov M; Kosmider O; Radford-Weiss I; Moura IC; Auberger P; Ifrah N; Bardet V; Chapuis N; Lacombe C; Mayeux P; Tamburini J; Bouscary D
    Blood; 2013 Nov; 122(20):3521-32. PubMed ID: 24014241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ASCT2 (SLC1A5)-dependent glutamine uptake is involved in the progression of head and neck squamous cell carcinoma.
    Zhang Z; Liu R; Shuai Y; Huang Y; Jin R; Wang X; Luo J
    Br J Cancer; 2020 Jan; 122(1):82-93. PubMed ID: 31819178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting SLC1A5 blocks cell proliferation through inhibition of mTORC1 in arsenite-treated human uroepithelial cells.
    Li S; Zhou Q; Liu W; Fu Z; Zhao H; Xi S
    Toxicol Lett; 2021 Jul; 345():1-11. PubMed ID: 33781819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Role of ASCT2 (SLC1A5) in KRAS-Mutated Colorectal Cancer.
    Toda K; Nishikawa G; Iwamoto M; Itatani Y; Takahashi R; Sakai Y; Kawada K
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28749408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer.
    van Geldermalsen M; Wang Q; Nagarajah R; Marshall AD; Thoeng A; Gao D; Ritchie W; Feng Y; Bailey CG; Deng N; Harvey K; Beith JM; Selinger CI; O'Toole SA; Rasko JE; Holst J
    Oncogene; 2016 Jun; 35(24):3201-8. PubMed ID: 26455325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA
    Jiang J; Dong W; Zhang W; Wang Q; Wang R; Wang J; Wu H; Dong H; Zhao RC; Wang J; Li Z
    Discov Med; 2023 Dec; 35(179):995-1014. PubMed ID: 38058065
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.